filipfoto/iStock via Getty Images Biodexa Pharmaceuticals ( NASDAQ: BDRX ) said on Friday it has received a letter from the Nasdaq stock market notifying the company about the delisting of its securities from Nasdaq Capital Market as they have had a closing bid price below $1 for 30 consecutive business days. The company said it intends to timely request a hearing to stay any suspension or delisting action. More on Biodexa Pharmaceuticals Biodexa stock rallies amid release of Phase 2 data for eRapa Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals.